Status:
UNKNOWN
Lactated Ringer's Solution in Neonates With Feeding Intolerance
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions:
Intestinal Disease
Feeding Disorder Neonatal
Eligibility:
All Genders
2+ years
Phase:
PHASE2
Brief Summary
The objective of this study is determining if enteral administration of Lactated Ringer's solution (LR) in preterm infants with feeding intolerance enables for faster advancement of milk feeding than ...
Detailed Description
Feeding intolerance is a common problem in premature infants in the Neonatal Intensive Care Unit. Definition is clinical and based on abdominal distension, abdominal tenderness, emesis, change in gast...
Eligibility Criteria
Inclusion
- Birth gestational age (GA) between 25 and 32 weeks
- Corrected gestational age less than 34 weeks
- Enteral feeding tolerated at a minimum of 10 ml/kg/day for a minimum of 48 hours
- Severe feeding intolerance, defined as a minimum of one or more of the following signs leading to withholding of milk feedings on two evaluations over 12 to 24 hours:
- Significant increased abdominal girth, as evaluated by the treatment team, with abdominal tenderness
- Visible enlarged bowel loops with abdominal tenderness
- Recurrent emesis leading to withhold feeds
- Gastric residuals in excess of one feeding, recurrent or with growing abdominal girth
- Visible blood in stools without anal etiology
- Documented informed consent for participation in the study
Exclusion
- Infants who already reached full enteral feeds for 72 hours, in fact a minimum of 130 ml/kg/day enteral feeds without parenteral supplementation.
- Small for gestational age (SGA) (weight at or less than the 3rd percentile on the Fenton growth chart)
- NEC (Bell's stage II or higher, radiologic evidence of NEC, pneumatosis intestinalis or free intraperitoneal air)or history of NEC
- Gastric or intestinal occlusion (no transit, absent bowel sounds, incessant vomiting, bile stained vomiting or air fluid levels)
- Major congenital malformation
- Septic infants requiring therapeutic antibiotics or antimycotics (infants only on prophylactic antibiotics or antimycotics should not be excluded).
- Patients judged as being too ill to enroll in this study, as defined by a requirement for mechanical ventilation with \>50% FIO2
- Patent Ductus Arteriosus requiring ibuprofen, indomethacin or ligature, until one week after the end of treatment
- Intraventricular Haemorrhage grade 3 or 4
- Hypernatremia ≥ 150 mmol/L
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2012
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01236833
Start Date
November 1 2010
End Date
September 1 2012
Last Update
August 4 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
McGill University Health Center
Montreal, Quebec, Canada, H3H 2R9
2
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2